BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design and Setting
2.2. Patient Population and Procedures
2.3. Statistical Analysis
3. Results
3.1. Patient Population and Baseline Characteristics
3.2. Follow-Up and Outcomes
3.3. Dietary Exposures and 1-Year Recurrence
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| Abbreviation | Definition |
| ASA24 | Automated Self-Administered 24 h Dietary Assessment Tool |
| BCG | Bacillus Calmette–Guérin |
| Be-Well | Bladder cancer Epidemiology and Wellness study |
| BMI | Body mass index |
| CI | Confidence interval |
| CREA | Council for Agricultural Research and Economics |
| ECOG | Eastern Cooperative Oncology Group |
| EFSA | European Food Safety Authority |
| FDR | False discovery rate |
| FOODCONS | Food Consumption Database |
| IL | Interleukin |
| IQR | Interquartile range |
| LTFU | Lost to follow-up |
| MAI | Mediterranean Adequacy Index |
| NMIBC | Non-muscle-invasive bladder cancer |
| OR | Odds ratio |
| RCT | Randomized Controlled Trial |
| SD | Standard deviation |
| TURBT | Transurethral resection of bladder tumor |
| Th1 | T helper type 1 |
| Th2 | T helper type 2 |
References
- Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2024, 74, 229–263. [Google Scholar] [CrossRef]
- Babjuk, M.; Burger, M.; Capoun, O.; Cohen, D.; Compérat, E.M.; Dominguez Escrig, J.L.; Gontero, P.; Liedberg, F.; Masson-Lecomte, A.; Mostafid, A.H.; et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur. Urol. 2022, 81, 75–94. [Google Scholar] [CrossRef]
- Zlotta, A.R.; Fleshner, N.E.; Jewett, M.A. The management of BCG failure in non-muscle-invasive bladder cancer: An update. Can. Urol. Assoc. J. 2009, 3, S199–S205. [Google Scholar] [CrossRef] [PubMed]
- Kwan, M.L.; Wang, Z.; Haque, R.; Lee, V.S.; Roh, J.M.; Ergas, I.J.; Cannavale, K.L.; Pratt, R.; Goniewicz, M.; Loo, R.K.; et al. The influence of dietary isothiocyanates on the effectiveness of mitomycin C and Bacillus Calmette–Guérin in treating nonmuscle-invasive bladder cancer. J. Urol. 2024, 212, 420–430. [Google Scholar] [CrossRef] [PubMed]
- Westhoff, E.; Wu, X.; Kiemeney, L.A.; Lerner, S.P.; Ye, Y.; Huang, M.; Dinney, C.P.; Vrieling, A.; Tu, H. Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int. J. Cancer 2018, 142, 1797–1804. [Google Scholar] [CrossRef]
- European Food Safety Authority (EFSA). Guidance on the EU Menu methodology. EFSA J. 2014, 12, 3944. [Google Scholar] [CrossRef]
- Mistura, L.; Azcarraga, F.J.C.; D’Addezio, L.; Le Donne, C.; Martone, D.; Piccinelli, R.; Sette, S. Comparing Self-Administered Web-Based to Interviewer-Led 24-h Dietary Recall (FOODCONS): An Italian Pilot Case Study. Dietetics 2025, 4, 17. [Google Scholar] [CrossRef]
- Beaton, G.H.; Milner, J.; Corey, P.; McGuire, V.; Cousins, M.; Stewart, E.; de Ramos, M.; Hewitt, D.; Grambsch, P.V.; Kassim, N.; et al. Sources of variance in 24-hour dietary recall data: Implications for nutrition study design and interpretation. Am. J. Clin. Nutr. 1979, 32, 2546–2559. [Google Scholar] [CrossRef] [PubMed]
- Dodd, K.W.; Guenther, P.M.; Freedman, L.S.; Subar, A.F.; Kipnis, V.; Midthune, D.; Tooze, J.A.; Krebs-Smith, S.M. Statistical methods for estimating usual intake of nutrients and foods: A review of the theory. J. Am. Diet. Assoc. 2006, 106, 1640–1650. [Google Scholar] [CrossRef]
- Crispim, S.P.; de Vries, J.H.M.; Geelen, A.; Souverein, O.W.; Hulshof, P.J.M.; Lafay, L.; Rousseau, A.-S.; Lillegaard, I.T.L.; Andersen, L.F.; van ’t Veer, P.; et al. Two non-consecutive 24 h recalls using EPIC-Soft software are sufficiently valid for comparing protein and potassium intake between five European centres—results from the European Food Consumption Validation (EFCOVAL) study. Br. J. Nutr. 2011, 105, 447–458. [Google Scholar] [CrossRef]
- Firth, D. Bias reduction of maximum likelihood estimates. Biometrika 1993, 80, 27–38. [Google Scholar] [CrossRef]
- Heinze, G.; Ploner, M.; Dunkler, D.; Southworth, H. logistf: Firth’s Bias-Reduced Logistic Regression. R Package Version 1.26.1. 2025. Available online: https://cran.r-project.org/package=logistf (accessed on 20 December 2025).
- Willett, W.C.; Howe, G.R.; Kushi, L.H. Adjustment for total energy intake in epidemiologic studies. Am. J. Clin. Nutr. 1997, 65, 1220S–1228S. [Google Scholar] [CrossRef]
- Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B 1995, 57, 289–300. [Google Scholar] [CrossRef]
- R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2025. [Google Scholar]
- Lidagoster, S.; Ben-David, R.; De Leon, B.; Sfakianos, J.P. BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer. Curr. Oncol. 2024, 31, 1063–1078. [Google Scholar] [CrossRef]
- Böhle, A.; Brandau, S. Immune mechanisms in Bacillus Calmette–Guérin immunotherapy for superficial bladder cancer. J. Urol. 2003, 170, 964–969. [Google Scholar] [CrossRef]
- Abou Chakra, M.; Luo, Y.; Duquesne, I.; O’Donnell, M.A. Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer. Front. Biosci. (Landmark Ed.) 2024, 29, 295. [Google Scholar] [CrossRef]
- van Puffelen, J.H.; Novakovic, B.; van Emst, L.; Kooper, D.; Zuiverloon, T.C.M.; Oldenhof, U.T.H.; Witjes, J.A.; Galesloot, T.E.; Vrieling, A.; Aben, K.K.H.; et al. Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections. J. Immunother. Cancer 2023, 11, e005518. [Google Scholar] [CrossRef] [PubMed]
- Rink, L.; Kirchner, H. Zinc-altered immune function and cytokine production. J. Nutr. 2000, 130, 1407S–1411S. [Google Scholar] [CrossRef] [PubMed]
- Prasad, A.S. Zinc in human health: Effect of zinc on immune cells. Mol. Med. 2008, 14, 353–357. [Google Scholar] [CrossRef] [PubMed]
- Ferro, M.; Di Lorenzo, G.; Vartolomei, M.D.; Bruzzese, D.; Cantiello, F.; Lucarelli, G.; Musi, G.; Di Stasi, S.; Hurle, R.; Guazzoni, G.; et al. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving Bacillus Calmette–Guérin after transurethral resection of the bladder tumor. World J. Urol. 2020, 38, 143–150. [Google Scholar] [CrossRef]
- Xu, C.; Zeng, X.T.; Liu, T.Z.; Zhang, C.; Yang, Z.H.; Li, S.; Chen, X.Y. Fruits and vegetables intake and risk of bladder cancer: A PRISMA-compliant systematic review and dose-response meta-analysis of prospective cohort studies. Medicine 2015, 94, e759. [Google Scholar] [CrossRef] [PubMed]
- Wang, S.; Ge, C. High risk of non-cancer mortality in bladder cancer patients: Evidence from SEER-Medicaid. J. Cancer Res. Clin. Oncol. 2023, 149, 10203–10215. [Google Scholar] [CrossRef]
- Alberti-Fidanza, A.; Fidanza, F. Mediterranean Adequacy Index of Italian diets. Public Health Nutr. 2004, 7, 937–941. [Google Scholar] [CrossRef]
- Lenis, A.T.; Asanad, K.; Blaibel, M.; Donin, N.M.; Chamie, K. Association between metabolic syndrome and recurrence of nonmuscle invasive bladder cancer following Bacillus Calmette–Guérin treatment. Urol. Pract. 2018, 5, 132–138. [Google Scholar] [CrossRef]
- Ferro, M.; Vartolomei, M.D.; Russo, G.I.; Cantiello, F.; Farhan, A.R.A.; Terracciano, D.; Musi, G.; Busetto, G.M.; Hurle, R.; Damiano, R.; et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J. Urol. 2019, 37, 507–514. [Google Scholar] [CrossRef] [PubMed]
- van Zutphen, M.; Hof, J.P.; Aben, K.K.H.; Kampman, E.; Witjes, J.A.; Kiemeney, L.A.L.M.; Vrieling, A. Adherence to lifestyle recommendations after non-muscle invasive bladder cancer diagnosis and risk of recurrence. Am. J. Clin. Nutr. 2023, 117, 681–690. [Google Scholar] [CrossRef] [PubMed]
- Morze, J.; Danielewicz, A.; Przybyłowicz, K.; Zeng, H.; Hoffmann, G.; Schwingshackl, L. An updated systematic review and meta-analysis on adherence to Mediterranean diet and risk of cancer. Eur. J. Nutr. 2021, 60, 1561–1586. [Google Scholar] [CrossRef]
- Rock, C.L.; Thomson, C.A.; Sullivan, K.R.; Howe, C.L.; Kushi, L.H.; Caan, B.J.; Neuhouser, M.L.; Bandera, E.V.; Wang, Y.; Robien, K.; et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J. Clin. 2022, 72, 230–262. [Google Scholar] [CrossRef]
- Muscaritoli, M.; Arends, J.; Bachmann, P.; Baracos, V.; Barthelemy, N.; Bertz, H.; Bozzetti, F.; Hütterer, E.; Isenring, E.; Kaasa, S.; et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin. Nutr. 2021, 40, 2898–2913. [Google Scholar] [CrossRef]
- Moshfegh, A.J.; Rhodes, D.G.; Baer, D.J.; Murayi, T.; Clemens, J.C.; Rumpler, W.V.; Paul, D.R.; Sebastian, R.S.; Kuczynski, K.J.; Ingwersen, L.A.; et al. The US Department of Agriculture Automated Multiple-Pass Method reduces bias in the collection of energy intakes. Am. J. Clin. Nutr. 2008, 88, 324–332. [Google Scholar] [CrossRef]
- Kirkpatrick, S.I.; Subar, A.F.; Douglass, D.; Zimmerman, T.P.; Thompson, F.E.; Kahle, L.L.; George, S.M.; Dodd, K.W.; Potischman, N. Performance of the Automated Self-Administered 24-hour Recall relative to a measure of true intakes and to an interviewer-administered 24-h recall. Am. J. Clin. Nutr. 2014, 100, 233–240. [Google Scholar] [CrossRef] [PubMed]
- Drapeau, V.; Laramée, C.; Lafrenière, J.; Trottier, C.; Brochu, C.; Robitaille, J.; Lamarche, B.; Lemieux, S. Assessing the relative validity of a web-based self-administered 24-hour dietary recall in a Canadian adolescent’s population. Nutr. J. 2024, 23, 66. [Google Scholar] [CrossRef] [PubMed]
- Chotwanvirat, P.; Prachansuwan, A.; Sridonpai, P.; Kriengsinyos, W. Advancements in Using AI for Dietary Assessment Based on Food Images: Scoping Review. J. Med. Internet Res. 2024, 26, e51432. [Google Scholar] [CrossRef]
- Yan, R.; Luo, H.; Lu, J.; Liu, D.; Posluszny, H.; Dhaliwal, M.P.; MacLeod, J.; Qin, Y.; Yang, C.; Hartman, T.J.; et al. DietAI24 as a framework for comprehensive nutrition estimation using multimodal large language models. Commun. Med. 2025, 5, 458. [Google Scholar] [CrossRef] [PubMed]

| Characteristic | N (%) or Mean (SD) | Median (IQR); Min–Max |
|---|---|---|
| Sex | Males: 42 (91.3%); Females: 4 (8.7%) | |
| Age, years | 65.5 (8.2) | 67.0 (59.3–71.0); 45–79 |
| Total energy intake, kcal/day | 1770.0 (450.6) | 1729.4 (1422.0–2101.6); 1017.8–2789.6 |
| Weight, kg | 84.6 (12.0) | 80.0 (76.3–94.8); 60–110 |
| Height, cm | 172.5 (7.0) | 172.5 (170.0–178.0); 155–185 |
| Body mass index, kg/m2 | 28.4 (3.5) | 27.5 (26.3–30.0); 23.2–40.4 |
| Mediterranean Adequacy Index (MAI) | 2.6 (1.2) | 2.25 (1.80–3.15); 0.7–5.9 |
| Pathologic stage, pT1 | 33/46 (71.7%) | |
| Pathologic stage, pTa | 13/46 (28.3%) | |
| BCG induction completed | 42/46 (91.3%) | |
| Planned 1-year BCG course completed | 31/42 (73.8%); data missing for 4 participants | |
| 1-year recurrence status available | 41/46 (89.1%); data missing for 5 participants | |
| 1-year recurrence among those available | 8/41 (19.5%) | |
| 1-year progression status available | 41/46 (89.1%); data missing for 5 participants | |
| 1-year progression among those available | 3/41 (7.3%) |
| Exposure (Group 1: Food Groups) | OR | 95% CI | p-Value | q-Value | N (Events) |
|---|---|---|---|---|---|
| Meat, processed meats, and meat substitutes | 0.566 | 0.209 to 1.216 | 0.148 | 0.593 | 41 (8) |
| Cereals, bakery products, and cereal substitutes | 2.035 | 0.854 to 6.358 | 0.116 | 0.593 | 41 (8) |
| Fruit, fresh and processed | 0.510 | 0.183 to 1.167 | 0.115 | 0.593 | 41 (8) |
| Legumes, fresh and processed | 0.609 | 0.012 to 1.255 | 0.212 | 0.635 | 41 (8) |
| Oils and fats | 0.665 | 0.210 to 1.490 | 0.351 | 0.843 | 41 (8) |
| Milk, dairy products, and milk substitutes | 0.805 | 0.336 to 1.684 | 0.576 | 0.863 | 41 (8) |
| Eggs | 1.207 | 0.589 to 2.413 | 0.575 | 0.863 | 41 (8) |
| Vegetables, fresh and processed | 1.295 | 0.561 to 2.979 | 0.534 | 0.863 | 41 (8) |
| Alcoholic beverages and substitutes | 1.079 | 0.254 to 2.159 | 0.857 | 0.969 | 41 (8) |
| Sweets and substitutes | 1.013 | 0.466 to 1.944 | 0.969 | 0.969 | 41 (8) |
| Potatoes, tubers, and products | 0.933 | 0.277 to 2.256 | 0.890 | 0.969 | 41 (8) |
| Fish and seafood | 1.091 | 0.469 to 2.361 | 0.828 | 0.969 | 41 (8) |
| Exposure (Group 2: Selected Food Items) | OR | 95% CI | p-Value | q-Value | N (Events) | Consumers, n (%) |
|---|---|---|---|---|---|---|
| Extra-virgin olive oil and olive oil | 0.533 | 0.149 to 1.306 | 0.191 | 0.361 | 41 (8) | 41 (100.0%) |
| Coffee | 1.974 | 0.869 to 5.652 | 0.107 | 0.361 | 41 (8) | 41 (100.0%) |
| Raw tomatoes | 0.622 | 0.220 to 1.382 | 0.258 | 0.361 | 41 (8) | 23 (56.1%) |
| Cooked tomatoes | 1.770 | 0.765 to 5.090 | 0.192 | 0.361 | 41 (8) | 38 (92.7%) |
| Dark chocolate | 1.612 | 0.655 to 3.486 | 0.233 | 0.361 | 41 (8) | 11 (26.8%) |
| Leafy green vegetables | 0.385 | 0.101 to 0.972 | 0.043 | 0.361 | 41 (8) | 33 (80.5%) |
| Nuts | 1.608 | 0.721 to 3.387 | 0.213 | 0.361 | 41 (8) | 14 (34.1%) |
| Milk, yogurt, and cheese | 0.803 | 0.333 to 1.682 | 0.572 | 0.728 | 41 (8) | 40 (97.6%) |
| Tap water | 1.129 | 0.521 to 2.205 | 0.730 | 0.852 | 41 (8) | 21 (51.2%) |
| Cruciferous vegetables | 0.934 | 0.427 to 1.884 | 0.847 | 0.913 | 41 (8) | 18 (43.9%) |
| Cured meats (cold cuts) | 0.982 | 0.469 to 1.785 | 0.953 | 0.953 | 41 (8) | 31 (75.6%) |
| Citrus fruits | 0.492 | 0.062 to 1.240 | 0.168 | 0.361 | 41 (8) | 27 (65.9%) |
| Red meat | 0.478 | 0.112 to 1.112 | 0.092 | 0.361 | 41 (8) | 36 (87.8%) |
| Water | 0.352 | 0.085 to 1.108 | 0.076 | 0.361 | 41 (8) | 41 (100.0%) |
| Exposure (Group 3: Nutrients) | OR | 95% CI | p-Value | q-Value | N (Events) |
|---|---|---|---|---|---|
| Zinc | 0.280 | 0.069 to 0.802 | 0.015 | 0.385 | 41 (8) |
| Magnesium | 0.260 | 0.045 to 0.872 | 0.025 | 0.385 | 41 (8) |
| Total protein | 0.513 | 0.132 to 1.132 | 0.104 | 0.445 | 41 (8) |
| Complex carbohydrates | 1.921 | 0.855 to 5.251 | 0.121 | 0.445 | 41 (8) |
| Iron | 0.442 | 0.097 to 1.199 | 0.129 | 0.445 | 41 (8) |
| Potassium | 0.387 | 0.114 to 0.983 | 0.046 | 0.445 | 41 (8) |
| Phosphorus | 0.559 | 0.215 to 1.180 | 0.129 | 0.445 | 41 (8) |
| Riboflavin (vitamin B2) | 0.509 | 0.181 to 1.164 | 0.112 | 0.445 | 41 (8) |
| Vitamin B6 | 0.540 | 0.189 to 1.185 | 0.129 | 0.445 | 41 (8) |
| Vitamin C | 0.523 | 0.145 to 1.224 | 0.148 | 0.460 | 41 (8) |
| Oleic acid | 0.563 | 0.163 to 1.353 | 0.220 | 0.515 | 41 (8) |
| Monounsaturated fatty acids | 0.591 | 0.183 to 1.391 | 0.249 | 0.515 | 41 (8) |
| Available carbohydrates | 1.660 | 0.734 to 4.356 | 0.236 | 0.515 | 41 (8) |
| Thiamine (vitamin B1) | 0.570 | 0.138 to 1.308 | 0.213 | 0.515 | 41 (8) |
| Niacin (vitamin B3) | 0.620 | 0.230 to 1.340 | 0.230 | 0.515 | 41 (8) |
| Polyunsaturated fatty acids | 1.455 | 0.639 to 3.036 | 0.330 | 0.639 | 41 (8) |
| Linoleic acid | 1.384 | 0.600 to 2.860 | 0.400 | 0.688 | 41 (8) |
| Vitamin E | 0.714 | 0.262 to 1.513 | 0.399 | 0.688 | 41 (8) |
| Linolenic acid | 1.397 | 0.502 to 2.986 | 0.437 | 0.700 | 41 (8) |
| Beta-carotene | 1.279 | 0.636 to 2.634 | 0.451 | 0.700 | 41 (8) |
| Fiber | 0.738 | 0.241 to 1.738 | 0.510 | 0.752 | 41 (8) |
| Cholesterol | 1.219 | 0.569 to 2.571 | 0.591 | 0.809 | 41 (8) |
| Soluble carbohydrates | 0.824 | 0.327 to 1.771 | 0.630 | 0.809 | 41 (8) |
| Retinol | 1.141 | 0.315 to 1.978 | 0.668 | 0.809 | 41 (8) |
| Vitamin K | 0.844 | 0.324 to 1.780 | 0.675 | 0.809 | 41 (8) |
| Vitamin B12 | 0.842 | 0.272 to 1.764 | 0.679 | 0.809 | 41 (8) |
| Total fat | 0.879 | 0.359 to 1.890 | 0.752 | 0.863 | 41 (8) |
| Saturated fatty acids | 1.089 | 0.485 to 2.243 | 0.821 | 0.909 | 41 (8) |
| Calcium | 1.047 | 0.432 to 2.323 | 0.913 | 0.943 | 41 (8) |
| Vitamin D | 0.966 | 0.348 to 1.694 | 0.909 | 0.943 | 41 (8) |
| Alcohol | 1.005 | 0.219 to 2.196 | 0.992 | 0.992 | 41 (8) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Buonerba, C.; Baio, R.; Crocetto, F.; Bruzzese, D.; Del Giudice, F.; Nacchia, A.; Chiancone, F.; Ingenito, C.; Strianese, O.; Verde, A.; et al. BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG. Curr. Oncol. 2026, 33, 128. https://doi.org/10.3390/curroncol33020128
Buonerba C, Baio R, Crocetto F, Bruzzese D, Del Giudice F, Nacchia A, Chiancone F, Ingenito C, Strianese O, Verde A, et al. BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG. Current Oncology. 2026; 33(2):128. https://doi.org/10.3390/curroncol33020128
Chicago/Turabian StyleBuonerba, Carlo, Raffaele Baio, Felice Crocetto, Dario Bruzzese, Francesco Del Giudice, Antonio Nacchia, Francesco Chiancone, Concetta Ingenito, Oriana Strianese, Antonio Verde, and et al. 2026. "BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG" Current Oncology 33, no. 2: 128. https://doi.org/10.3390/curroncol33020128
APA StyleBuonerba, C., Baio, R., Crocetto, F., Bruzzese, D., Del Giudice, F., Nacchia, A., Chiancone, F., Ingenito, C., Strianese, O., Verde, A., Costabile, F., Scafuri, L., Sanseverino, R., Sorrentino, E., Riccio, V., Carino, D., Bertoni, M., Monaco, F., Verze, P., ... Di Lorenzo, G. (2026). BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG. Current Oncology, 33(2), 128. https://doi.org/10.3390/curroncol33020128

